Novagali Pharma and Ardeo Sign an Exclusive Distribution Agreement for Nova23041 in the United States and Canada
June 09 2011 - 1:15PM
Business Wire
Regulatory News:
Novagali Pharma (Paris:NOVA), a pharmaceutical company
that develops innovative ophthalmic products, can today announce
that it has signed an exclusive agreement with Ardeo Health, LLC
for Nova23041 its unique formulation for the treatment of dry eye
symptoms in the United States and Canada with OCuSOFT, Inc.
Nova23041 is a preservative-free oil-in-water emulsion resulting
from Novasorb® patented technology whose efficiency and tolerance
in treating dry eye symptoms have been proven during a number of
clinical trials carried out in Europe and Southeast Asia.
Based on the electrostatic attraction between the positively
charged eye drop and the negatively charged ocular surface,
Novasorb®’s technological platform enables the product to be spread
in an optimal, uniform and comfortable way across the entire ocular
surface, improves resilience time and thus reduces the number of
instillations necessary with increased efficiency and optimal
compliance and tolerance.
Nova23041 has been successfully marketed since 2008 under the
brand name Cationorm®, a brand that belongs to Novagali Pharma. The
product is already recommended by ophthalmologists in numerous
countries throughout Europe, North Africa, the Middle East and
Southeast Asia.
Thanks to this exclusive distribution agreement, Nova23041 will
be marketed in the United States and Canada under the brand name
Retaine® MGD™ Ophthalmic Emulsion. OCuSOFT, Inc. will become the
exclusive promoter.
Cynthia Barratt, President of OCuSOFT, comments: “OCuSOFT has
been searching for a truly unique proprietary Dry Eye therapy which
also combined a long-term partnership – and we have found that with
Ardeo Health and Novagali. I believe Retaine® MGD™ will become the
standard of care for those suffering with Meibomian Gland
deficiencies.”
“Everyone at Ardeo Health is excited to see this newest
technology brought to North America. Patients suffering from Dry
Eye will now have an alternative to expensive prescription (Rx)
therapies”, states Robert “Bob” Sykora, RPh, President & CEO of
Ardeo Health. “With these partnerships, Ardeo has the best of both
worlds – the science of Novagali coupled with the brand recognition
and distribution channels of OCuSOFT®.”
Jérôme Martinez, Chairman of Novagali Pharma, concludes: “We are
very pleased to be able to announce, today, the signing of this
agreement involving two major American ophthalmology players. Given
their proven expertise on the North American ophthalmology market,
OCuSOFT’s teams will no doubt make Nova23041’s launch in the United
States and Canada a success that will enable us to extend the
distribution of our unique formulation for treating dry eye
symptoms around the world. This agreement confirms the growing
reputation in the United States of the products and technologies
developed by Novagali Pharma. Novagali Pharma also plans to get the
results of the Catioprost® phase II study in the United States
during the third quarter of 2011”.
About NOVAGALI Pharma -
www.novagali.comFounded in 2000, Novagali Pharma SA is a
pharmaceutical company that develops ophthalmic innovative products
for all segments of the eye. Thanks to its three proprietary
technology platforms, the Company has an advanced portfolio of
highly innovative products, one of which is already on sale and two
of which are undergoing phase III clinical trials.In 2009, Frost
& Sullivan recognised Novagali with the Award for Industry
Innovation & Advancement of the Year, for its proprietary
emulsion technology platforms, and Siemens awarded the company the
“Health Award” Grand Prix de l’Innovation for Novasorb®. Novagali
Pharma carried out a successful IPO in July 2010 enabling the
Company to raise €22 million.Novagali Pharma is listed on NYSE
Euronext Paris - Compartment C. ISIN code: FR0010915553 - Ticker:
NOVA.
About Ardeo Health LLC -
www.ardohealth.comArdeo Health is a Suwanee, GA USA.-based
healthcare company that specializes in research, development, and
licensing of advanced technology pharmaceutical products, consumer
health products, and medical devices. Ardeo Health is dedicated to
the pursuit of products and technologies leading to the effective
treatment and cure of ophthalmic and dermatologic diseases. For
more information, please contact: info@ardeohealth.com
About OCuSOFT, Inc. -
www.ocusoft.comOCuSOFT, Inc. is a Richmond, TX USA-based
ophthalmic research, development and supply company with an
established reputation for innovation, particularly in the area of
Ocular Surface Disease (OSD). Since 1986, OCuSOFT® has served the
ophthalmic industry with a unique selection of proprietary brands
including over-the-counter (OTC) and prescription products. A
pioneer in ophthalmology, OCuSOFT® introduced the first eyelid
cleanser, the first topical anesthetic gel, the first “leave-on”
antibacterial eyelid cleaner, the first prescription-only
supplement for Dry Eyes and the first supplement to enhance
botulinum toxin injections. Today, the company is most recognized
for its #1 Doctor Recommended Brand of Eyelid Cleansers, OCuSOFT®
Lid Scrub™, in addition to its standing as the preferred
distributor of ophthalmic products and supplies by eye care
professionals in the U.S. For more information, please contact
Linda Dang at ldang@ocusoft.com or by calling 800-233-5469
(U.S.)
DisclaimerThis press release
contains forward-looking statements. Although Novagali Pharma
considers these statements to be based on reasonable assumptions,
they could be affected by risks and uncertainties causing actual
results to differ significantly from these forward-looking
statements. For details of the risks and uncertainties that could
potentially affect Novagali Pharma’s results, financial situation,
performances or achievements and thus result in a variation in
these figures compared to the forward-looking statements contained
in this document, please refer to the Risk Factors section of the
Document de Base source document registered with the French
Autorité des Marches Financiers (“AMF”) under n° R. 11-021 on April
29th 2011 and available on the AMF (http://www.amf-france.org) and
Novagali Pharma (www.novagali.com) websites.This press release and
the information contained herein do not constitute an offer to sell
or subscribe to, or a solicitation of an offer to buy or subscribe
to, shares in Novagali Pharma in any country.
Next press
releaseRevenue for the 2nd quarter and
1st half of 2011:July 28th 2011
(after market)
Novagali Pharma is listed on NYSE Euronext
Paris - Compartment CISIN code: FR0010915553 - Ticker: NOVA
Novo Nordisk (TG:NOVA)
Historical Stock Chart
From Oct 2024 to Nov 2024
Novo Nordisk (TG:NOVA)
Historical Stock Chart
From Nov 2023 to Nov 2024
